



A Case Report on Rheumatic Heart Disease

Akshatha ^a, Greeshma Raju ^{b++}, Vibitha Vinod ^{b++},
Sara Babu ^{b++}, Angel Sunny ^{b++}, Nagarjuna D ^{c#*}
and RS Meghasri ^{d#}

^a V Pharm D, TVM College of Pharmacy, Ballari, Karnataka, India.

^b TVM College of Pharmacy, Ballari, Karnataka, India.

^c Department of Pharmacy Practice, TVM College of Pharmacy, Ballari, Karnataka, 583104, India.

^d Department of Pharmacy Practice, Akshaya Institute of Pharmacy, Tumakur, Karnataka, 572106, India.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: <https://doi.org/10.9734/jpri/2024/v36i97575>

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/121619>

Case Report

Received: 20/06/2024

Accepted: 22/08/2024

Published: 24/08/2024

ABSTRACT

Background: Rheumatic heart disease is caused secondary to rheumatic fever. Rheumatic fever, a systemic immune response to a beta-hemolytic streptococcal throat infection, remains a significant health issue in developing countries.

Clinical Findings: This is a case report of Rheumatic heart disease in which a 19-year-old female patient was admitted to the hospital with chief complaints of cough with expectoration for 3 months (sputum of minimal quantity, white to yellowish in colour), bilateral lower limb swelling and joint pains for 2 months insidious in onset gradually progressive in nature. She did not have any comorbidities. So, based on her signs and symptoms the physician has advised her for CBC, 2D

⁺⁺ Pharm D Intern;

[#] Assistant Professor;

^{*}Corresponding author: E-mail: damarlanagarjuna83@gmail.com;

Cite as: Akshatha, Greeshma Raju, Vibitha Vinod, Sara Babu, Angel Sunny, Nagarjuna D, and RS Meghasri. 2024. "A Case Report on Rheumatic Heart Disease". *Journal of Pharmaceutical Research International* 36 (9):38-45. <https://doi.org/10.9734/jpri/2024/v36i97575>.

Echo, ECG, C3 & C4 test, chest X-ray, urine routine & analysis, thyroid profile, anti-nuclear antibody test (ANA) and ASLO (antistreptolysin) test. In which her hemoglobin, RBC, WBC and platelets levels were abnormal. Chest X-ray shown presence of cardiomegaly, Urine routine & Analysis shown 4-5 pus cells and 1-2 epithelial cells are seen/hpf. 2D echo shown Dilated chamber, Global LV dysfunction EF- 40%, MVP severe MR: PML (posterior mitral leaflet) calcified, Moderate Aortic regurgitation (AR), Inferior vena cava dilated. ECG shown sinus rhythm, T wave inversion on V1-V3. ASLO test was 549.5 mg/dL which confirms recent streptococcal infection.

Management: The treatment was initiated with Antibiotics, Proton pump inhibitors, Antiemetics, Diuretics, Anti-hypertensive, Corticosteroids and NSAID's etc.

Outcome: Therefore Rheumatic heart disease can be prevented by preventing streptococcal infections or treating them with Antibiotics when they occur.

Keywords: Rheumatic heart disease (RHD); rheumatic fever; beta-hemolytic streptococcal; cardiomegaly; LV dysfunction; aortic regurgitation; mitral regurgitation (MR); mitral valve prolapse (MVP).

1. INTRODUCTION

Rheumatic heart disease is caused secondary to rheumatic fever. Rheumatic fever, a systemic immune response to a beta-hemolytic streptococcal throat infection, causing around 320,000 deaths annually among young people [1]. Acute rheumatic fever (ARF) primarily affects children aged 5-15 and is uncommon in those over 30, about 60% of ARF cases progress to rheumatic heart disease (RHD), which Heart Murmurs, Fatigue, Shortness of Breath, Chest Pain, Palpitations, Swollen Joints and Fever characterise. It primarily affects the mitral and aortic valves. The mitral valve is affected in 75-80% of cases, the aortic valve in 30%, and the tricuspid and pulmonary valves in less than 5% [1].

Mitral Valve Prolapse (MVP) is a condition where the two valve flaps of the mitral valve do not close smoothly or evenly but instead bulge (prolapse) upward into the left atrium during the heart's contraction. This can sometimes lead to blood leaking backward into the left atrium. Mitral Regurgitation (MR) occurs when the mitral valve doesn't close tightly, allowing blood to flow backward into the left atrium when the left ventricle contracts. This backward flow can cause symptoms such as fatigue and shortness of breath, as the heart must work harder to move blood through the body [2]. Dilated cardiomyopathy (DCM) is a heart muscle disorder characterized by a dilated and poorly functioning left ventricle, occurring without abnormal loading conditions (such as hypertension or valve disease) or ischemic heart disease that could cause global systolic impairment [3].

Table 1. Standard treatment for rheumatic heart disease [4]

Antibiotic	Dose	Route	Frequency	Duration
<i>First-line treatment</i>				
Benzathine penicillin G (BPG)	1 200 000 U (body weight \geq 27 kg) 600 000 U (body weight < 27 kg)	Deep intramuscular injection	4 weekly, or 3 weekly for selected groups	All people with ARF or RHD: Minimum 10 years after most recent episode of ARF or until age 21 years (whichever is longer)
Amoxicillin	50 mg/kg (Max. 1g)	Intra vascular	Once daily	
Second-line treatment (if intramuscular routine not possible or refused)				
Phenoxy methylpenicillin (penicillin V)	250 mg	Oral	Thrice daily	Status after initial period has elapsed: <ul style="list-style-type: none"> No RHD or mild RHD: discontinue at that time Moderate RHD: continue until age 35 years Severe RHD: continue until age 40 years or longer
Treatment in cases of documented penicillin allergy				
Clindamycin	20 mg/kg	Oral	Thrice daily	
Azithromycin	12 mg/kg	Oral	Once daily	
Clarithromycin	15 mg/kg	Oral	Twice daily	
Cephalosporin	variable	Oral		
Minimally invasive procedure	valvuloplasty to widen the valve			
Surgery	heart valve surgery Ross procedure			

2. CASE REPORT

A 19-year-old female patient was admitted in Vijayanagara Institute of medical science, Ballari (Karnataka) with chief complaints of cough with expectoration for 3 months (sputum of minimal quantity, white to yellowish in colour), bilateral lower limb swelling and joint pains since 2 months insidious in onset gradually progressive in nature. On examination, patient was conscious and oriented, BP-120/80mmHg, PR 84 beats/min, P/A-soft, non-tender, no organomegaly and bowel sounds +ve, CVS-

S1S2+, R/S-B/L NVBS+. She did not have any comorbidities.

Provisional diagnosis: Acute rheumatic fever, post streptococcal glomerulonephritis, nephrotic syndrome (?)

Final diagnosis: Rheumatic heart disease with mitral valve prolapse and severe mitral regurgitation, dilated cardiomyopathy with severe left ventricular dysfunction.

Treatment: She was started with the following medications.

Table 2. Patient laboratory report

Laboratory test	Lab parameters	Results				
		D1	D3	D6	D9	D11
Haematology	Haemoglobin (12-16 g/dl)	9.0	8.8	8.6	8.9	11.3
	RBC (3.5-5.0 million/cmm)	5.88	5.64	5.38	5.81	6.74
	WBC (4000-11000 cells/cumm)	17570	14050	23700	17670	16550
	PCV (33-43 %)	32	30.3	29.0	31.4	38.5
	MCV (76-100 fl)	54.4	53.8	53.9	54.0	57.1
	MCH (27-33 pg/cell)	15.3	15.6	16.0	15.3	16.8
	MCHC (33-37 g/dl)	28.0	29.0	29.8	28.3	29.4
	Platelets (1.5-4.5 lacs/cumm)	1.63	4.62	2.24	4.88	7.25
	ESR (0-20 mm/hr)	18				
	LFT	Total protein (6 – 8.3 g/dL)	5.6	5.8	6.3	
Albumin (3.2 - 5.4 g/dL)		2.9	3.0	3.0		
Globulin (2.5 – 3 g/dL)		2.7	2.8	3.3		
A: G (1.2 – 1.5)		1.1	1.1	0.9		
Total bilirubin (0.1-1mg/dL)		1.2	1.3	1.5		
Conj. Bilirubin (0-1.2 mg/dL)		0.5	0.5	0.7		
Unconj. Bilirubin (0.1-0.8))		0.7	0.8	0.8		
ALT (0.35 U/L)		22	16	24		
AST (0-35 U/L)		10	15	10		
ALP (32-120 U/L)		67	63	59		
RFT	Blood urea (20-50mg/dL)	20	16	20		
	Serum creatinine (0.6-1.2mg/dL)	1.0	0.9	0.9		
Thyroid profile	T3 (0.202- 0.443 ng/dL)		0.26			
	T4 (0.92- 1.68 ng/dL)		1.75			
	TSH (0.27- 4.2 mIU/mL)		3.64			
Serology	CRP (0-6 mg/L)	52	114			
	RA factor	- ve				
	C3 (90- 180 mg/dl)	105.4				
Serum electrolytes	C4 (10- 40 mg/dl)	25.5				
	Sodium	139	139	140		
	Potassium	4.1	3.4	3.9		
Biochemistry	Chloride	100	104	99		
	RBS	55	107			
Urine routine & Analysis	Urine microscopy	4-5 pus cells and 1-2 epithelial cells are seen/hpf.				
		NIL				
	Urine sugar	Present				
	Urine albumin	30.9 mgs%				
	Spot protein	99.5 mgs%				
	Spot creatinine	0.31, 0.75				
ASLO test (Antistreptolysin)	Protein/ creatinine ratio(<0.2)	549.5 mg/dl (Upto 200)				
	ANA	Weak positive				
2D echo	Dilated chamber					
	Global LV dysfunction EF- 40%					
	MVP severe MR: PML (posterior mitral leaflet) calcified					
	Moderate Aortic regurgitation (AR), Inferior vena cava dilated					
ECG	sinus rhythm, T wave inversion on V1-V3					




Fig. 1. Statistical analysis of lab data




Fig. 2. ECG suggestive sinus rhythm, T wave inversion on V1-V3



Fig. 3. Chest X-ray suggestive of cardiomegaly




Fig. 4. (A) Dilated cardiomyopathy (B) Mitral valve regurgitation




Fig. 5. Dilated inferior vena cava




Fig. 6. Left Ventricular dysfunction

Table 3. Treatment chart

SI No	Name of drugs	Dose	Route	Frequency	Days
1	Amoxicillin & Clavulanate	1.2 g	IV	1-0-1	D1-D11
2	Pantoprazole	40 mg	IV	1-0-0	D1-D11
3	Azithromycin	500 mg	PO	1-0-0	D1
4	Salbutamol	5 ml	PO	1-1-1	D1-D4
5	Neb Duolin & Budecort	6 th hrly	PN	1-1-1-1	D1-D2
6	Ondansetron	8 mg	IV	1-0-1 sos	D2-D3
7	Furosemide	20 mg	IV	1-1-0	D3-D11
8	Benzathine Penicillin	1.2 mu	IM		D2
9	Dexamethasone	4 mg	IV	1-1-1	D4-D11
10	Aspirin	300 mg	PO	Stat	D4-D11
		150 mg		1-1-1-1	
11	Metoprolol	25 mg	PO	1-0-1	D11

Table 4. Discharge medication

SI no	Name of Medication	Dose	Route	Frequency
1	Tab Aspirin	150 mg	PO	0-1-0
2	Tab Atorvastatin	40 mg	PO	0-0-1
3	Tab Furosemide	20 mg	PO	1-1-0
4	Inj Benzathine Penicillin	1.2 mu	IM	Every 21 days
5	Tab Pantoprazole	40 mg	PO	1-0-0

3. DISCUSSION

Rheumatic heart disease (RHD) is caused secondary to rheumatic fever which is caused due to untreated Group a Streptococcal (GAS) infection. When streptococcal bacteria invade the body, the immune system typically responds by identifying and eliminating the bacteria. In approximately 97% of cases, this immune response successfully clears the infection. However, in the remaining 2-3% of individuals who are genetically predisposed, the immune system mistakenly targets its own tissues. This occurs because the antigens of the streptococcal bacteria bear structural similarities to human antigens, a phenomenon known as antigenic mimicry. As a result, inflammation and tissue damage can occur, particularly affecting the heart, joints, skin, and central nervous system (CNS) [5]. RHD is characterised by chest pain, shortness of breath, fatigue, palpitation, heart murmur, lower limb swelling and cough. It mainly affects valves of our heart particularly mitral and aortic valve and lead to complications of mitral regurgitation, mitral or valvular stenosis, mitral valve prolapse, left ventricular dysfunction and dilated cardiomyopathy. In this case the patient mitral valve was affected.

In this case a 19-year-old female patient was admitted with chief complaints of cough with expectoration since 3 months (sputum of minimal quantity, white to yellowish in colour), bilateral lower limb swelling and multiple joint pains since 2 months insidious in onset gradually progressive

in nature. Her past medical history reveals that she did not have any comorbidities so based on her sign and symptoms the physician has advised her for hematology, 2D Echo, ECG, C3 & C4 test, chest X-ray, urine routine & analysis, thyroid profile, anti nuclear antibody test (ANA) and ASLO (antistreptolysin) test. In which her hemoglobin, RBC, WBC and platelets levels were abnormal. Chest X-ray shown presence of cardiomegaly, Urine routine & Analysis shown 4-5 pus cells and 1-2 epithelial cells are seen/hpf. 2D echo shown Dilated chamber, Global LV dysfunction EF- 40%, MVP severe MR: PML (posterior mitral leaflet) calcified, Moderate Aortic regurgitation (AR), Inferior vena cava dilated. ECG shown sinus rhythm, T wave inversion on V1-V3. ASLO test was 549.5 mg/dL which confirms recent streptococcal infection, ANA shows weak positive and C3, C4, Thyroid tests were normal (Table 2).

The treatment was initiated with amoxiclav which is a combination of amoxicillin and clavulanate to treat bacterial infection, Pantoprazole to treat gastro-intestinal irritation, azithromycin to treat bacterial infection, salbutamol and nebulisation duolin & budecort to treat breathlessness, ondansetron given as a prophylactic treatment, furosemide to treat edema, Benzathine penicillin to treat streptococcal infection, dexamethasone to treat inflammation, aspirin to treat heart disease, metoprolol to treat hypertension but in this patient tab metoprolol has been prescribed without any indication (Table 3).

The treatment was initiated as per standard treatment guidelines. Patient's disease condition got improved, cough and bilateral lower limb swelling have resolved, and joint pain has improved during the hospital stay. As the patient remained stable, they were discharged from the hospital with the following medications Aspirin to treat heart disease, atorvastatin to prevent high cholesterol levels, furosemide to treat edema, Benzathine penicillin (every 21 days for life time) to treat streptococcal infection and pantoprazole to treat gastro-intestinal irritation (Table 4). Physician advised patient to review after 10 days.

The patient's condition was managed using a combination of antibiotics, anti-inflammatory drugs, and supportive care, which aligns with standard treatment protocols for RHD (Table 1) [6]. Comparative studies show that early intervention with antibiotics like Benzathine penicillin G remains the cornerstone of preventing RHD progression, as noted in other studies such Ambari AM et al. (2024) Adherence to penicillin treatment is essential for effective secondary prevention of rheumatic heart disease: a systematic review and meta-analysis [7].

4. CONCLUSION

Rheumatic heart disease is a condition where the heart valves have been permanently damaged by Rheumatic fever. Rheumatic heart disease can be prevented by preventing streptococcal infections or treating them with Antibiotics when they occurred. Untreated or under treated strep infections put the patient at increased risk. Treatment depends on how much damage has been done to the heart valves. It may even include surgery to replace a badly damaged valve. The best way to avoid RHD is to treat strep throat when patient has suffering, start using Antibiotic immediately. When strep is treated properly it does not have the opportunity to turn into Rheumatic fever and cause heart problems.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

We hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of manuscripts.

CONSENT

As per international standards or university standards, patient(s) written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

As per international standards or university standards written ethical approval has been collected and preserved by the author(s).

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Rime Abbas, Michael J Aminoff et al. Current medical diagnosis & treatment (CMDT). 63rd ed. San Francisco: McGraw-Hill Education. 2024;379.
2. Mayo Clinic. Mitral Valve Prolapse. Available: <https://www.mayoclinic.org/diseases-conditions/mitral-valve-prolapse/symptoms-causes/syc-20355446>. Accessed June 30, 2024.
3. Amelin F, Hariyanto D, Izzah AZ. Dilated cardiomyopathy concomitant with acute rheumatic fever and sporadic hereditary spherocytosis. Health and Medical Journal. 2020, Jul 26;2(2):78-86.
4. Carapetis JR, Brown A, Wilson NJ, Edwards KN. An Australian guideline for rheumatic fever and rheumatic heart disease: An abridged outline. Medical Journal of Australia. 2007, Jun;186(11): 581-6.
5. Simpson MT, Kachel M, Neely RC, Erwin WC, Yasin A, Patel A, Rao DP, Pandey K, George I. Rheumatic heart disease in the developing world. Structural Heart. 2023, Sep 19;100219:1-9. DOI:org/10.1016/j.shj.2023.100219.
6. Rentta NN, Bennett J, Leung W, Webb R, Jack S, Harwood M, Baker MG, Lund M, Wilson N. Medical treatment for rheumatic heart disease: A narrative review. Heart, Lung and Circulation. 2022, Nov 1;31(11): 1463-70.
7. Ambari AM, Radi B, Dwiputra B, Arityanti D, Rikl T, Inggriani MP, Qhabibi FR, Susilowati E, Makes IK, Rudiktyo E, Cramer MJ. Adherence to penicillin

treatment is essential for effective secondary prevention of rheumatic heart disease: A systematic review

and meta-analysis. *Annals of Medicine and Surgery.* 2024, Apr 1;86(4): 2116-23.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of the publisher and/or the editor(s). This publisher and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:

<https://www.sdiarticle5.com/review-history/121619>